CS787487A2 - Process for preparing new derivatives of tetrahydronaphthalene - Google Patents
Process for preparing new derivatives of tetrahydronaphthaleneInfo
- Publication number
- CS787487A2 CS787487A2 CS877874A CS787487A CS787487A2 CS 787487 A2 CS787487 A2 CS 787487A2 CS 877874 A CS877874 A CS 877874A CS 787487 A CS787487 A CS 787487A CS 787487 A2 CS787487 A2 CS 787487A2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- alkyl
- dion
- benzodiazepine
- imidazo
- interrupted
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 title 1
- -1 tri-substituted 2-imidazolyl Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 abstract 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 abstract 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 230000002213 calciumantagonistic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Insulating Materials (AREA)
- Luminescent Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH456586 | 1986-11-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS787487A2 true CS787487A2 (en) | 1988-11-15 |
| CS264350B2 CS264350B2 (en) | 1989-07-12 |
Family
ID=4278454
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS877874A CS264350B2 (en) | 1986-11-14 | 1987-11-03 | Process for preparing new derivatives of tetrahydronaphthalene |
| CS913948A CS394891A3 (en) | 1986-11-14 | 1991-12-20 | Tetrahydronaphthalene derivatives and pharmaceuticals based thereon |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS913948A CS394891A3 (en) | 1986-11-14 | 1991-12-20 | Tetrahydronaphthalene derivatives and pharmaceuticals based thereon |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US4808605A (cs) |
| EP (1) | EP0268148B1 (cs) |
| JP (1) | JP2504490B2 (cs) |
| KR (1) | KR960004863B1 (cs) |
| CN (1) | CN1028991C (cs) |
| AT (1) | ATE70267T1 (cs) |
| AU (1) | AU600769B2 (cs) |
| BG (1) | BG60937B2 (cs) |
| CA (1) | CA1319144C (cs) |
| CS (2) | CS264350B2 (cs) |
| DE (2) | DE19775076I2 (cs) |
| DK (1) | DK171349B1 (cs) |
| DZ (1) | DZ1142A1 (cs) |
| ES (1) | ES2040234T3 (cs) |
| FI (1) | FI94414C (cs) |
| GR (1) | GR3004029T3 (cs) |
| HK (1) | HK110494A (cs) |
| HU (1) | HU215915B (cs) |
| IE (1) | IE60695B1 (cs) |
| IL (1) | IL84407A (cs) |
| LV (1) | LV5745B4 (cs) |
| MC (1) | MC1883A1 (cs) |
| MX (1) | MX173614B (cs) |
| NL (1) | NL970019I2 (cs) |
| NO (2) | NO172237C (cs) |
| NZ (1) | NZ222474A (cs) |
| PH (1) | PH23919A (cs) |
| PT (1) | PT86130B (cs) |
| SG (1) | SG114194G (cs) |
| ZA (1) | ZA878362B (cs) |
| ZW (1) | ZW20087A1 (cs) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003283A1 (en) * | 1988-12-05 | 1990-06-05 | C. Anne Higley | Imidazoles for the treatment of atherosclerosis |
| CA2011461A1 (en) * | 1989-03-20 | 1990-09-20 | Urs Hengartner | Tetrahydronaphthalene derivatives |
| NL9001522A (nl) * | 1990-07-04 | 1992-02-03 | Schreiner Luchtvaart | Werkwijze voor het vervaardigen van een voorwerp bestaande uit een schuimkern en eventueel een of meer afdeklagen. |
| TW216770B (cs) * | 1991-07-23 | 1993-12-01 | Hoffmann La Roche | |
| US5565449A (en) * | 1991-10-18 | 1996-10-15 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5250679A (en) * | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| EP0793653A1 (en) * | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| DE69526073T2 (de) | 1995-06-23 | 2002-08-22 | Technische Universiteit Delft, Delft | Verfahren zur Herstellung eines schäumbaren Filmes |
| US5910606A (en) * | 1996-01-31 | 1999-06-08 | Hoffmann-La Roche Inc. | Process for making α,β-unsaturated carboxylic acids |
| US5808088A (en) * | 1997-04-30 | 1998-09-15 | Roche Colorado Corporation | Preparation of mibefradil via an acetamide anion |
| US5811556A (en) * | 1997-04-30 | 1998-09-22 | Roche Colorado Corporation | Preparation of mibefradil via a naphthalenylacetic acid |
| US5811557A (en) * | 1997-04-30 | 1998-09-22 | Roche Colorado Corporation | Preparation of mibefradil via an acetonitrile anion |
| US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
| US7101909B2 (en) * | 1998-10-12 | 2006-09-05 | Theravance, Inc. | Calcium channel drugs and uses |
| HUP0202143A3 (en) * | 1999-07-28 | 2003-12-29 | Ortho Mcneil Pharm Inc | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use |
| AU2001235364A1 (en) | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Tetrahydronaphtalene derivatives and their use |
| WO2001062740A1 (en) * | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Mibefradil analogues and their use |
| ES2274854T3 (es) * | 2000-05-08 | 2007-06-01 | Pfizer Products Inc. | Resolucion enzimatica de moduladores selectivos del receptor de estrogeno. |
| FR2827862A1 (fr) * | 2001-07-27 | 2003-01-31 | Lipha | Derives imidazolylalkylarylalcanoiques et leurs applications en therapeutique |
| WO2003031415A1 (en) * | 2001-10-10 | 2003-04-17 | Aryx Therapeutics | Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina |
| KR20030037081A (ko) * | 2001-11-02 | 2003-05-12 | 한국과학기술연구원 | Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법 |
| EA200500234A1 (ru) | 2002-08-19 | 2005-08-25 | Пфайзер Продактс Инк. | Комбинированная терапия гиперпролиферативных болезней |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| WO2005012296A1 (en) * | 2003-07-28 | 2005-02-10 | Janssen Pharmaceutica N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators |
| CA2574958A1 (en) * | 2004-07-26 | 2006-02-09 | Cotherix, Inc. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| WO2007050783A2 (en) | 2005-10-26 | 2007-05-03 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| EP2351569B1 (en) | 2005-10-26 | 2012-08-22 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| ATE547394T1 (de) | 2006-12-01 | 2012-03-15 | Bristol Myers Squibb Co | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen |
| CL2008000468A1 (es) * | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras. |
| JP4595040B2 (ja) * | 2007-04-27 | 2010-12-08 | アクテリオン ファーマシューティカルズ リミテッド | 架橋６員環化合物 |
| PT2268646E (pt) * | 2008-04-11 | 2013-12-10 | Janssen Pharmaceutica Nv | Aminas de tiazolopiridina-2-iloxi-fenil e de tiazolopirazina-2-iloxi-fenilo como moduladores da hidrolase de leucotrieno a4 |
| KR101364909B1 (ko) * | 2008-04-25 | 2014-02-21 | 액테리온 파마슈티칼 리미티드 | 칼슘 채널 차단제로서의 벤지미다졸 유도체 |
| US8314253B2 (en) | 2008-10-22 | 2012-11-20 | Actelion Pharmaceuticals Ltd. | Bridged tetrahydronaphthalene derivatives |
| WO2010046729A2 (en) * | 2008-10-23 | 2010-04-29 | Actelion Pharmaceuticals Ltd | Tetrahydronaphthalene compounds |
| WO2011006073A1 (en) | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| EP3144296A1 (en) * | 2010-03-02 | 2017-03-22 | Concert Pharmaceuticals, Inc. | Deuterated tetrahydronaphthalene derivatives |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| WO2012037665A1 (en) | 2010-09-24 | 2012-03-29 | Oral Delivery Technology Ltd. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions |
| CN105143203A (zh) | 2013-04-17 | 2015-12-09 | 辉瑞大药厂 | 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物 |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| EP3364993B1 (en) | 2015-10-22 | 2022-11-09 | Cavion, Inc. | Methods for treating angelman syndrome |
| CN110545806A (zh) * | 2017-02-15 | 2019-12-06 | 卡维昂公司 | 钙通道抑制剂 |
| EP3615521A4 (en) | 2017-04-26 | 2021-02-17 | Cavion, Inc. | METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS |
| JP7480131B2 (ja) | 2018-10-03 | 2024-05-09 | カビオン・インコーポレイテッド | （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| CN115850119A (zh) * | 2022-11-26 | 2023-03-28 | 南昌大学 | 一种2-氯芳香胺类化合物的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3914216A (en) * | 1962-12-18 | 1975-10-21 | Boehringer Sohn Ingelheim | 1-Phenyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-diones |
| BE793460A (fr) * | 1971-12-29 | 1973-06-28 | Boehringer Sohn Ingelheim | Nouvelles 1-aryl-3h,1,4-benzodiazepine-2,5-(1h |
| NZ213651A (en) * | 1984-10-11 | 1989-07-27 | Hoffmann La Roche | Tetrahydronapthalene derivatives and medicaments |
-
1987
- 1987-10-26 CA CA000550190A patent/CA1319144C/en not_active Expired - Fee Related
- 1987-10-26 DK DK559987A patent/DK171349B1/da not_active IP Right Cessation
- 1987-11-03 ZW ZW200/87A patent/ZW20087A1/xx unknown
- 1987-11-03 CS CS877874A patent/CS264350B2/cs not_active IP Right Cessation
- 1987-11-04 AT AT87116251T patent/ATE70267T1/de active
- 1987-11-04 ES ES198787116251T patent/ES2040234T3/es not_active Expired - Lifetime
- 1987-11-04 EP EP87116251A patent/EP0268148B1/de not_active Expired - Lifetime
- 1987-11-04 DE DE1997175076 patent/DE19775076I2/de active Active
- 1987-11-04 DE DE8787116251T patent/DE3775177D1/de not_active Expired - Lifetime
- 1987-11-06 ZA ZA878362A patent/ZA878362B/xx unknown
- 1987-11-06 NZ NZ222474A patent/NZ222474A/xx unknown
- 1987-11-09 AU AU80909/87A patent/AU600769B2/en not_active Ceased
- 1987-11-09 IL IL84407A patent/IL84407A/xx unknown
- 1987-11-10 JP JP62282287A patent/JP2504490B2/ja not_active Expired - Lifetime
- 1987-11-10 US US07/119,114 patent/US4808605A/en not_active Expired - Lifetime
- 1987-11-11 DZ DZ870191A patent/DZ1142A1/fr active
- 1987-11-11 PH PH36056A patent/PH23919A/en unknown
- 1987-11-11 HU HU875011A patent/HU215915B/hu not_active IP Right Cessation
- 1987-11-12 MC MC871928A patent/MC1883A1/fr unknown
- 1987-11-12 MX MX009271A patent/MX173614B/es unknown
- 1987-11-13 PT PT86130A patent/PT86130B/pt not_active IP Right Cessation
- 1987-11-13 IE IE307087A patent/IE60695B1/en not_active IP Right Cessation
- 1987-11-13 NO NO874757A patent/NO172237C/no not_active IP Right Cessation
- 1987-11-13 KR KR87012777A patent/KR960004863B1/ko not_active Expired - Fee Related
- 1987-11-13 CN CN87107875A patent/CN1028991C/zh not_active Expired - Fee Related
- 1987-11-13 FI FI875024A patent/FI94414C/fi not_active IP Right Cessation
-
1991
- 1991-12-20 CS CS913948A patent/CS394891A3/cs unknown
-
1992
- 1992-03-11 GR GR920400420T patent/GR3004029T3/el unknown
-
1994
- 1994-02-14 BG BG098469A patent/BG60937B2/bg unknown
- 1994-08-13 SG SG114194A patent/SG114194G/en unknown
- 1994-10-12 HK HK110494A patent/HK110494A/xx not_active IP Right Cessation
-
1996
- 1996-05-24 LV LV960155A patent/LV5745B4/xx unknown
-
1997
- 1997-05-27 NL NL970019C patent/NL970019I2/nl unknown
-
1998
- 1998-01-09 NO NO1998001C patent/NO1998001I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960004863B1 (en) | Tetrahydronaphthalene derivatives and its process | |
| FI883807A7 (fi) | Menetelmä farmakologisesti aktiivisten 7-(3-substituoitu-1-pyrrolidinyyli)-1-syklopropyyli-1,4-dihydro-4-okso-1,8-naftyridiini-3-karboksyylihappojohdannaisten valmistamiseksi | |
| NO176356C (no) | Analogifremgangsmåte for fremstilling av nye terapeutisk aktive pyrazolopyridinforbindelser | |
| IE780119L (en) | IMIDAZO(1,2-a) QUINOLINE-2-CARBOXYLIC ACIDS | |
| NO881835D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive bicykliske forbindelser. | |
| HUT46214A (en) | Process for producing medical preparation suitable for treatment of peptic ulcer | |
| AU586707B2 (en) | New 2-(2-thienyl)-imidazo(4,5-c)pyridine derivatives and salts thereof, processes for their preparation and pharmaceutical products containing these | |
| JPS57131788A (en) | 1,7-naphthyridine derivative | |
| NO177786B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrido-[2,3-bÅ-benzazepin- (og -tiazepin)-5(6H)-on-derivater | |
| JPS57131789A (en) | 1,7-naphthyridine derivative | |
| TH9786A (th) | อนุพันธ์เซฟาโลสพอรินและกรรมวิธีสำหรับเตรียม | |
| JPS6440485A (en) | Pyranoquinolinone derivative and pharmaceutical composition containing said compound as active component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20021103 |